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EDITORIAL
Antiretroviral therapy in resource-poor
settings: scaling up inequalities?
Matthias Egger,1* Andrew Boulle,2 Mauro Schechter3 and Paolo Miotti4
Since 1996, the increasingly widespread use of potent
antiretroviral therapy (ART), a combination of at least three
drugs from different classes, has transformed a fatal infection into
a chronic disease that is manageable in most patients.1–3
However, in resource-poor settings in Africa, Asia, and Latin
America, where 90% of people with HIV/AIDS live, access to
ART has so far been limited to a minority of patients, owing to the
high cost of drugs and the lack of an infrastructure capable of
delivering ART on a large scale. In recent years, costs of
proprietary drugs have fallen and low-cost generic preparations
have increasingly become available. Many African countries have
qualified for grants from the ‘Global Fund to fight AIDS,
Tuberculosis, and Malaria’. Worldwide, the Fund has approved
over 1 billion US dollars for programmes against HIV/AIDS.4 On
December 1, 2003 (World AIDS Day) WHO launched the ‘3 by 5’
initiative (3 million patients treated by 2005), whose strategy
involves simplified, standardized tools for delivering and
monitoring antiretroviral therapy.5 The American ‘President’s
Emergency Plan for AIDS Relief’ (PEPFAR) intends to give
2 million people access to ART.6 The government of South Africa,
one of the countries hardest hit by the AIDS epidemic, has
recently set up an ‘Operational Plan for Comprehensive HIV and
AIDS Care, Management and Treatment’ to make antiretroviral
drugs widely available in the public health system.7
Access to antiretroviral treatment has been steadily
improving; however, a large majority of people who need
treatment in developing and transitional countries still have no
access to it. Table 1 shows the ART coverage in HIV-infected
people aged 15–49 years at the end of 2004 in the 20 developing
or transitional countries with the highest number of people in
need of ART. About 80% of the total number of 5.8 million
patients urgently needing ART live in these countries, but in
most of them 10% of these patients received ART in
December 2004.8 Important exceptions with higher treatment
coverage include Uganda (40%), Thailand (44%), Botswana
(50%), and Brazil (86%).8 Clearly, the global health emergency
that was declared by the United Nations General Assembly in
20019 continues.
Act now and act well
There is increasing evidence that antiretroviral treatment in
resource-limited settings can be very effective. In Brazil, for
example, the national health system (Sistema Único de Saúde)
introduced free ART as soon as drugs became available,
including, from 1996 onwards, protease inhibitors; it also
provided for monitoring of the HIV disease using CD4 cell
counts and viral load.10 As a result, a national study of survival
among adult Brazilian AIDS patients diagnosed in 1995 and
1996 showed a substantial improvement of survival compared
with AIDS patients diagnosed in the 1980s.11 In the South
African township of Khayelitsha, which includes formal and
informal housing, three HIV/AIDS clinics started an ART
programme in 2001. A recent analysis of patients with
advanced immunodeficiency showed that the programme,
which involves trained lay counsellors and peer support,
achieved excellent adherence to treatment and good clinical
outcomes.12,13
The debate on ART in developing countries has irrevocably
moved from the question of whether the introduction of ART is
feasible in the light of competing priorities and fragile health
systems14,15 to questions of how effective ART and care can best
be delivered.16,17 Indeed, as Veronica Miller observes in her
commentary18 on the study of survival—without ART—of Thai
patients infected with HIV-1 subtype E19 published in this issue,
we should now put more emphasis on our research efforts with
regard to patients starting HAART in resource-poor settings and
support an evidence-based approach to the equitable provision
of potent ART in those settings. An important concern is
addressed by Antunes et al.20 in this issue of the journal: is it
possible to reduce AIDS deaths without reinforcing socioeco-
nomic inequalities in health?
Equitable access?
Antunes and colleagues examined trends in AIDS mortality in
districts of São Paulo, Brazil, during the period in which potent
ART was introduced in the Sistema Único de Saúde and found
that district level indicators of socioeconomic development (for
example average levels of income or education) were not
associated with declines in AIDS deaths, and that trends of
mortality were not poorer in deprived areas.20 These results
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refute, at least in the case of ART in São Paulo, the ‘inverse
equity hypothesis’, which stipulates that health inequities will
get worse as effective new public health interventions initially
reach those of higher socioeconomic status and only later the
poor.21 The study was ecological in nature and does not allow
inferences at the individual level. Also, in contrast to the era
before therapy became available, when the large majority of
deaths were associated with recent AIDS-defining events, AIDS
is only an incomplete measure of HIV-related deaths in the era
of potent ART.22 Nevertheless, it seems likely that in São Paulo
the large scale and free provision of ART meant that access to
therapies and quality of care was equitable, and patients of
different socioeconomic background were reached at around
the same time. This is a truly remarkable achievement but it
does not mean that the provision of ART is equitable in Brazil
at large, for example, between genders, urban and rural
populations, and between more affluent and poor or
marginalized populations in other regions of the country. In
Southern Africa, there is much concern that outside of cities,
there may be severe geographical inequalities in access to care,
and possibly an increasingly inequitable distribution of already
scarce health resources as a consequence of vertical, donor-
driven interventions for HIV.23 These concerns should never be
used to argue against an intervention of proven benefit but
rather be seen as a challenge to build a minimum health service
infrastructure in areas that currently are unable to deliver the
new intervention.
Muula recently illustrated the difficulties of making access to
ART equitable in Malawi.24 Problems start with the diagnosis of
HIV infection: the guidelines postulate that eligible patients
must produce written evidence of a positive HIV-test result,
which, according to Muula, cannot generally be obtained from
a public counselling and testing site but is easily purchased from
a private laboratory. This confirmation and a documented CD4
cell count of 200 cells per µl can rapidly establish eligibility for
ART. However, in Malawi, CD4 testing both in the public and
private sector is limited to large cities, which makes it likely that
relatively well-off urban dwellers will benefit from public sector
ART programmes more than the rural poor. In addition, the
WHO eligibility criteria are problematic in children: they
stipulate that an adult care giver must consent to HIV testing of
the child and then to the child’s treatment. As Muula points
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Table 1 Estimated antiretroviral therapy (ART) coverage in HIV-infected people aged 15–49 years in 2004 in developing and transitional
countries, December 2004
Number of people Number of people ART therapy
WHO region/country needing ART receiving ART coverage (%)a
African region
South Africa 837 000 37 000–62 000 7
Nigeria 558 000 12 000–150 00 2
Zimbabwe 295 000 75 000–9000 3
United Republic of Tanzania 263 000 2000–3500 1
Kenya 220 000 24 000–330 00 13
Ethiopia 211 000 10 000–130 00 5
Mozambique 199 000 6500–8000 4
Democratic Republic of the Congo 167 000 3500–4500 2
Zambia 149 000 18 000–22 000 13
Malawi 140 000 10 000–12 000 8
Uganda 114 000 40 000–50 000 40
Cameroon 95 000 12 000–15 000 14
Côte d’Ivoire 84 000 4000–5000 5
Botswana 75 000 36 000–39 000 50
Lesotho 56 000 2500–3000 5
South-east Asia region
India 770 000 20 000–36 000 4
Thailand 114 000 45 000–55 000 44
Region of the Americas
Brazil 179 000 151 000–157 000 86
Western Pacific region
China 122 000 7500–9500 7
European region
Russian Federation 92 000 3000–3500 3
The 20 countries with the highest number of people needing therapy are shown.
a Best coverage estimate based on the midpoints of the number of people receiving antiretrovirals. Adapted from WHO’s ‘3 by 5’ Progress Report,
December 2004.8
out,24 adults may not always act in the best interest of the child,
and laws to protect children are either lacking or not enforced.
AIDS orphans may be excluded simply because they do not
have access to an adult care giver. Finally, for children aged 18
months the criteria state that, ‘in the absence of virological
testing and CD4 cell assay availability, HIV-exposed infants 18
months of age should generally not be considered for ART
regardless of symptoms’. The virological testing required in this
situation is not available outside research laboratories in
Malawi, meaning that sick, HIV-infected children in this age
group may not receive ART.
Multilevel, multisite action research
WHO and other organizations stress that there are almost no
models for implementing ART programmes in resource-poor
settings, but that incomplete evidence should not constrain
efforts to scale up ART programmes. There is widespread
agreement that research and evaluation efforts are urgently
needed and must be synchronized, so that epidemiological and
clinical data can be collected and treatment programmes can be
modified and improved over time.5,6 For this to occur, questions
have to be asked at different levels, including the individual and
household, the treatment programme and health service, the
community, and the country and international level. Examples
of relevant clinical, operational, and policy questions are shown
in Table 2. While answering some of these questions will require
dedicated studies and surveys, other questions can be addressed
by the creative use of clinical databases and patient information
systems. A requisite for this type of multisite, multilevel research
is the collection across sites, using standardized methods and
definitions, of an agreed upon core set of clinical variables on
patients starting ART. For most resource-poor settings the
number of variables must be kept to a minimum so that data
collection can be integrated in routine care, while allowing the
option of collecting more data in tertiary care or research-based
centres. Ultimately, this approach should allow for meaningful
comparisons between several treatment programmes that differ
in terms of operational procedures and serve different
communities in different countries.
How can such research be funded? The Institute of Medicine
recommends that a fixed percentage of ART programme
funding be dedicated to monitoring, evaluation, and operational
research and that all stakeholders and donors agree on a
standard set of requirements.25 The Request for Applications
(RFA) for International Epidemiologic Databases to Evaluate
AIDS (IEDEA),26 which was recently issued by the US National
Institutes of Health is another approach that may provide
opportunities in this context. The aim is to establish regional
data centres in all continents, each being further divided into
several regions, to address HIV-related research questions. Such
data centres will compile datasets on diverse populations and
use the data to address research questions that cannot be
answered by one site alone. This endeavour is expected to allow
regions to more accurately characterize their HIV epidemic,
monitor critical outcomes of interventions, and generate future
research and programmatic hypotheses. In the years to come,
IEDEA and future complementary initiatives may provide a
much needed platform for global health services research and
represent a timely attempt to assess in a rigorous fashion the
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Table 2 Scaling up antiretroviral treatment: examples of research
questions at different levels
Level Research question
Individual and When should treatment be started?
household
How can treatment be monitored if laboratory 
facilities are limited?
When should treatment be changed?
What is the quality of life of treated patients 
and what toxicities and adverse events do 
they experience?
How does treatment affect patients’ preventive 
behaviours?
What is the impact of treatment on the 
household economy?
Treatment Is access to treatment and care equitable?
programme
How should patients be prepared for treatment to
maximize adherence and 
reduce adverse events?
What is the place of family-based approaches
to treatment?
What is the role of other interventions, including 
nutritional interventions and 
supplements?
What is the role of the private sector and of 
traditional medicine?
What are the main points of entry into the
treatment programme?
Community What is the role of community-based treatment 
support, for example, community health 
workers?
What are the levels of stigma and how does 
stigma and discrimination affect treatment 
programmes and outcomes?
Health systems How can treatment programmes best be
integrated with other programmes, including 
tuberculosis and mother and child health 
programmes?
What is the appropriate level of staffing of 
treatment programmes and what is the role of 
medical assistants?
How can the supply of medicines be secured and
made sustainable?
Country How will treatment scale-up influence the course
of the epidemic?
What is the impact on macro-economic indicators?
International How can the agenda of trade organizations, 
governments, donor agencies, and the 
pharmaceutical industry be influenced?
real-world impact of ART, including its impact on inequalities
in health.
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